This article was originally published April 7.
Roche Diagnostics and a number of Spanish collaborators have launched a study that will use 454 sequencing to profile hepatitis B and C virus populations in patients in order to identify drug-resistant viral quasispecies, Roche said last week.
For the project, Roche has partnered with the Vall d'Hebron Institute of Research in Barcelona, the Networking Biomedical Research Centre in Liver and Digestive Diseases, and software producer Advanced Biological Laboratories Therapy Edge Spain.
The study will use 454 sequencing in conjunction with "other genetic and molecular analytical techniques" to profile hepatitis virus populations in individuals, according to the company.
The aim is to apply sequencing "to personalize the antiviral treatment strategies in individuals with chronic hepatitis C or B."
The Vall d'Hebron institute acquired a 454 GS FLX in 2009 and said at the time that it would use the system to study hepatitis drug resistance and for the MetaHIT metagenomics project.
The new study is in line with 454's plans to develop targeted research assays for its sequencers in various disease areas. Earlier this month, 454 launched two research-use-only HLA typing assays for the GS FLX and the GS Junior (CSN 4/5/2011).